Dr. Scott Gottlieb was in an awkward position.
He’s been head of the Food and Drug Administration for just two weeks, and his boss, President Trump, is pushing a federal budget that would undo years of congressional work and risk bringing the agency to a grinding halt.
Speaking of 25 years, 2107 celebrates the launch of Ambien on the market. The review time was 47 months, which was the norm back then. Except for life threatening illness, perhaps we should go back to the pre PDUFA review times, which would also improve safety and fit within Trump’s budget framework. Problem is the incentive compensation structure in Pharmaland is geared to short term performance, and would have be revised, ultimately meaning fewer dollars to renew that membership at the local yacht club and the trophy spouse only gets to drive an A6 instead of an A8.
Comments are closed.